Table 1.
Baseline Characteristics of the Enrolled Patients.
| Before PS matching | After PS matching | ||||||
|---|---|---|---|---|---|---|---|
| Vonoprazan (n=27,101) | Oral PPI (n=51,863) | SD (%) | Vonoprazan (n=27,098) | Oral PPI (n=27,098) | SD (%) | ||
| Age (y), median (IQR) | 71 (61-81) | 71 (61-81) | 0.2 | 71 (61-81) | 71 (61-81) | 1.6 | |
| Sex, n (%) | |||||||
| Male | 18,726 (69.1) | 35,280 (68.0) | 1.9 | 18,724 (69,1) | 18,679 (69.0) | 0.2 | |
| Female | 8,375 (30.9) | 16,583 (32.0) | 1.9 | 8,374 (30.9) | 8,409 (31.0) | 0.2 | |
| BMI (kg/m2), median (IQR) | 21.9 (19.5-24.5) | 21.8 (19.5-24.3) | 3.8 | 21.9 (19.5-24.5) | 22.0 (19.6-24.5) | 0.6 | |
| CCI, median (IQR) | 0 (0-1) | 0 (0-1) | 3.0 | 0 (0-1) | 0 (0-1) | 0.0 | |
| Hemodialysis,n (%) | 638 (2.4) | 1,352 (2.6) | 1.0 | 638 (2.4) | 630 (2.3) | 0.5 | |
| Hospital volume, n (%) | |||||||
| Low (0-80) | 7,420 (27.4) | 14,551 (28.1) | 1.3 | 7,416 (27.4) | 7,253 (27.1) | 0.6 | |
| Intermediate (81-144) | 6,880 (25.4) | 13,575 (26.2) | 1.5 | 6,880 (25.4) | 7,047 (26.0) | 1.1 | |
| High (145-242) | 7,243 (26.7) | 13,283 (25.6) | 2.0 | 7,242 (26.7) | 7,107 (25.9) | 1.5 | |
| Very high (>242) | 5,558 (20.5) | 10,454 (20.2) | 0.6 | 5,557 (20.5) | 5,681 (21.0) | 1.0 | |
| Drug use, n (%) | |||||||
| Aspirin | 3,658 (13.5) | 6,129 (11.8) | 4.2 | 3,656 (13.5) | 3,638 (13.4) | 0.2 | |
| Cilostazol | 489 (1.8) | 833 (1.6) | 1.3 | 488 (1.8) | 485 (1.8) | 0.0 | |
| P2Y12RA | 1,373 (5.1) | 2,261 (4.4) | 2.7 | 1,371 (5.1) | 1,384 (5.1) | 0.0 | |
| Other antiplatelet drugs | 435 (1.6) | 683 (1.3) | 2.1 | 434 (1.6) | 404 (1.5) | 0.7 | |
| Warfarin | 1,114 (4.1) | 2,454 (4.7) | 2.4 | 1,113 (4.1) | 1,106 (4.1) | 0.0 | |
| DOAC | 1,372 (5.1) | 1,820 (3.5) | 6.6 | 1,371 (5.1) | 1,279 (4.7) | 1.5 | |
| Heparin | 1,414 (5.2) | 2,478 (4.8) | 1.5 | 1,414 (5.2) | 1,485 (5.5) | 1.1 | |
| Other anticoagulants | 16 (0.1) | 43 (0.1) | 0.0 | 16 (0.1) | 20 (0.1) | 0.0 | |
| NSAIDs | 1,454 (5.4) | 2,998 (5.8) | 1.1 | 1,454 (5.4) | 1,463 (5.4) | 0.0 | |
| Mucosal protective agents | 13,091 (48.3) | 25,168 (48.5) | 0.3 | 13,089 (48.3) | 13,162 (48.6) | 0.5 | |
| Corticosteroids | 637 (2.4) | 1,812 (3.5) | 5.2 | 637 (2.4) | 620 (2.3) | 0.5 | |
| PPI injection period (day), median (IQR) | 3 (2-4) | 3 (2-4) | 21.1 | 3 (2-4) | 3 (2-4) | 0.0 | |
PS: propensity score, PPI: proton pump inhibitor, SD: standardized difference, IQR: interquartile range, BMI: body mass index, CCI: Charlson comorbidity index, P2Y12RA: P2Y12 receptor antagonist, DOAC: direct oral anticoagulant, NSAIDs: non-steroidal anti-inflammatory drugs